Vega Masignani

Siena, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine.

Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine.

Journal: mSphere
Published: April 08, 2025

De-risking vaccine development: lessons, challenges, and prospects.

De-risking vaccine development: lessons, challenges, and prospects.

Journal: NPJ vaccines
Published: March 20, 2025

Next generation of "magic bullets", solutions from the microbial pangenome.

Next generation of "magic bullets", solutions from the microbial pangenome.

Journal: EMBO molecular medicine
Published: July 26, 2024

Neisserial adhesin A (NadA) binds human Siglec-5 and Siglec-14 with high affinity and promotes bacterial adhesion/invasion.

Neisserial adhesin A (NadA) binds human Siglec-5 and Siglec-14 with high affinity and promotes bacterial adhesion/invasion.

Journal: mBio
Published: July 23, 2024

Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines.

Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines.

Journal: mSphere
Published: September 21, 2022

Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NL096.

Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NL096.

Journal: Computational and structural biotechnology journal
Published: March 30, 2021

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.

Journal: PLoS pathogens
Published: March 25, 2020

Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity.

Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity.

Journal: Nature communications
Published: November 13, 2019

Lectin activity of Pseudomonas aeruginosa vaccine candidates PSE17-1, PSE41-5 and PSE54.

Lectin activity of Pseudomonas aeruginosa vaccine candidates PSE17-1, PSE41-5 and PSE54.

Journal: Biochemical and biophysical research communications
Published: March 05, 2019

The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.

The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.

Journal: Frontiers in immunology
Published: December 06, 2018

Meningococcal B vaccine (4CMenB): the journey from research to real world experience.

Meningococcal B vaccine (4CMenB): the journey from research to real world experience.

Journal: Expert review of vaccines
Published: November 21, 2018

Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa.

Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa.

Journal: Frontiers in immunology
Published: September 17, 2018
Showing 1-12 of 33

Last Updated: 09/26/2026